
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is well-positioned for success with its innovative products EsoCheck and EsoGuard, and with a potential for Medicare coverage for EsoGuard in mid-2026. The company has a large market potential of $60 billion, as well as strong support from GI specialty associations. Considering its strong balance sheet and planned product expansion into treatment, the company is poised for strong revenue growth which makes it an attractive investment opportunity.
Bears say
Lucid Diagnostics is facing several challenges in the competitive medical diagnostics market, despite the large potential market for their products. Despite recent progress with Medicare coverage and a potential catalyst in the ramping up of commercialization and sales, the company's Q3 results fell short of expectations and they continue to generate relatively low revenue. Additionally, with a negative net income and a relatively high projected EV/sales multiple, it is difficult to see a positive short-term outlook for this company.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares